PD-Inhibitor Benefits ' Continue Beyond Progression ' in NSCLC PD-Inhibitor Benefits ' Continue Beyond Progression ' in NSCLC
Non-small cell lung cancer patients can benefit from immunotherapy even after progression, from both drug continuance and the ongoing effect of prior treatment on salvage therapy, reveal two studies.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study